Retrospective analysis of 119 cases of pediatric acute promyelocytic leukemia: Comparisons of four treatment regimes

Experimental and Therapeutic Medicine

Volumn 4, Issue 1, 2012, Pages 93-98

  Li, En Qin ^a   Xu, Ling ^b   Zhang, Zhi Quan ^a   Xiao, Yan ^a   Guo, Hai Xia ^c   Luo, Xue Qun ^d   Hu, Qun ^a   Lai, Dong Bo ^b   Tu, Li Ming ^e   Jin, Run Ming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Acute promyelocytic leukemia; Chemotherapy; Myelogenous; Pediatric; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; HERBACEOUS AGENT; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; REALGAR INDIGO NATURALIS FORMULA; RETINOIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHILD; DIFFERENTIATION SYNDROME; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRY LIP; FEMALE; FLUID RETENTION; HEADACHE; HEART ARRHYTHMIA; HUMAN; LABORATORY TEST; LEUKEMIA REMISSION; LIP DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 84865768610     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.546     Document Type: Article

References (34)

1. Smith MA, Ries LA, Gurney JG, et al (eds): Leukemia. In: Cancer incidence and survival among children and adolescents. United States SEER Program 1975-1995. National Cancer Institute, SEER Program, Bethesda, MD, pp 17-34, 1999.
2. Cantu-Rajnoldi A, Biondi A, Jankovic M, et al: Diagnosis and incidence of acute promyelocytic leukemia (FAB M3 and M3 variant) in childhood. Blood 81: 2209-2210, 1993.
3. Catovsky D, Matutes E, Buccheri V, et al: A classification of acute leukaemia for the 1990s. Ann Hematol 62: 16-21, 1991.
4. de Thé H and Chen Z: Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 10: 775-783, 2010.
5. Lo-Coco F and Ammatuna E: The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program 514: 156-161, 2006.
6. Avvisati G, Petti MC, Lo-Coco F, et al: Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 100: 3141-3146, 2002.
7. Mann G, Reinhardt D, Ritter J, et al: Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 80: 417-422, 2001.
8. de Botton S, Coiteux V, Chevret S, et al: Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 22: 1404-1412, 2004.
9. Testi AM, Biondi A, Lo Coco F, et al: GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 106: 447-453, 2005.
10. Ortega JJ, Madero L, Martin G, et al: Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol 23: 7632-7640, 2005.
11. Powell B, Moser B, Stock W, et al: Preliminary results from the North American acute promyelocytic leukemia (APL) study C9710 (abstract). Blood 108: 566, 2006.
12. Luo XQ, Ke ZY, Huang LB, et al: Improved outcome for Chinese children with acute promyelocytic leukemia: a comparison of two protocols. Pediatr Blood Cancer 53: 325-328, 2009.
13. Gregory J, Kim H, Alonzo T, et al: Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer 53: 1005-1010, 2009.
14. Jeddi R, Ghedira H, Ben Abdennebi Y, et al: ATRA and anthracycline-based chemotherapy in the treatment of childhood acute promyelocytic leukemia (APL): a 10-year experience in Tunisia. Med Oncol 28: 1618-1623, 2010.
15. Creutzig U, Zimmermann M, Dworzak M, et al: Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol 149: 399-409, 2010.
16. Imaizumi M, Tawa A, Hanada R, et al: Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol 152: 89-98, 2011.
17. Kim MH CC, Lee JW, Jang PS, et al: Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol. Korean J Hematol 45: 236-241, 2010.
18. Ribeiro RC and Rego E: Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program 2006: 162-168, 2006.
19. Yeh TC, Liu HC, Wang LY, et al: The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. J Pediatr Hematol Oncol 29: 826-831, 2007.
20. Zhang L, Zhao H, Zhu X, et al: Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience. Pediatr Blood Cancer 51: 210-215, 2008.
21. Avvisati G, Lo Coco F, Diverio D, et al: AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 88: 1390-1398, 1996.
22. De Botton S, Chevret S, Coiteux V, et al: Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia 17: 339-342, 2003.
23. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8: 813-819, 1990.
24. Sanz MA, Lo Coco F, Martin G, et al: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96: 1247-1253, 2000.
25. Huang S, Guo A, Xiang Y, et al: Clinical study on the treatment of acute promyelocytic leukemia with composite Indigo Naturalis tablets. Chin J Hematol 16: 26-28, 1995.
26. The cooperation group of phase II. Clinical trial of compound Huangdai tablet: phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol 12: 801-804, 2006.
27. Wang L, Zhou GB, Liu P, et al: Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105: 4826-4831, 2008.
28. Xiang Y: The influence on long-term survey of the patients with acute promyelocytic leukemia treated with compound Huangdai tablets and chemotherapy. Chin J Clin Hematol 16: 204-206, 2007.
29. Rizzari C and Biondi A: Tailoring treatment strategy for acute promyelocytic leukemia in low-income countries. Pediatr Blood Cancer 53: 303-305, 2009.
30. Preisler H, Davis RB, Kirshner J, et al: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 69: 1441-1449, 1987.
31. Dillman RO, Davis RB, Green MR, et al: A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 78: 2520-2626, 1991.
32. Schiller G, Gajewski J, Nimer S, et al: A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol 81: 170-177, 1992.
33. Weick JK, Kopecky KJ, Appelbaum FR, et al: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88: 2841-2851, 1996.
34. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331: 896-903, 1994.